Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

81.81 +2.65 (+3.35%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
From HKTDC
Via ACN Newswire
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated. 
Via Stocktwits
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
From Daiichi Sankyo
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Announces Third-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors. 
Via Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
Via The Motley Fool
Topics Earnings Economy World Trade
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Stocks
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze 
Via MarketBeat
Topics Government
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Merck & Co., Inc.
Via Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector. 
Via Chartmill
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Daiichi Sankyo
Via Business Wire
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Topics Artificial Intelligence
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
From Merck & Co., Inc.
Via Business Wire
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.